



Office of Commissioner
Rebecca Kelly Slaughter

WASHINGTON, D.C. 20580

Regarding the Policy Statement of the Federal Trade Commission on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products

June 16, 2022

I'm pleased to support the Commission's Policy Statement on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products ("Statement"). This Statement affirms the Commission's commitment to use its full authority under the FTC Act to help tackle the illegal practices that result in high drug prices or reduced innovation.

We may also find that our authority to stop unfair or deceptive acts and practices maps onto misconduct in pharmaceutical pricing practices. For example, when we sued Martin Shkreli